Dr Ramachandra Rahul Vachan Chemitiganti, MD | |
701 W 5th St, Odessa, TX 79763-4206 | |
(432) 335-1777 | |
(432) 335-1815 |
Full Name | Dr Ramachandra Rahul Vachan Chemitiganti |
---|---|
Gender | Male |
Speciality | Endocrinology |
Experience | 26 Years |
Location | 701 W 5th St, Odessa, Texas |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1689610164 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | M9209 (Texas) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Medical Center Hospital | Odessa, TX | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Texas Tech University Health Sciences Center Odessa | 8426044256 | 44 |
News Archive
Researchers from the Polytechnic Institute of New York University and NYU have received a grant from the National Institutes of Health (NIH) to further a novel approach to understanding the genetic underpinnings of diseases including cancer and diabetes.
Neuralstem, Inc. announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin two Phase I safety trials to test NSI-189, its first small molecule compound, for the treatment of major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression.
Canadian students are back in the classroom, but some will find the experience a challenge. It's estimated that as many as six per cent of school age children have poor coordination that affects their ability to learn.
The NHS will receive an extra £5.4 billion over the next six months to support its response to COVID-19 and help tackle waiting lists, the Prime Minister and Health and Social Care Secretary Sajid Javid have announced today.
› Verified 5 days ago
Entity Name | Texas Oncology Pa |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1811944101 PECOS PAC ID: 5395658934 Enrollment ID: O20031124000323 |
News Archive
Researchers from the Polytechnic Institute of New York University and NYU have received a grant from the National Institutes of Health (NIH) to further a novel approach to understanding the genetic underpinnings of diseases including cancer and diabetes.
Neuralstem, Inc. announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin two Phase I safety trials to test NSI-189, its first small molecule compound, for the treatment of major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression.
Canadian students are back in the classroom, but some will find the experience a challenge. It's estimated that as many as six per cent of school age children have poor coordination that affects their ability to learn.
The NHS will receive an extra £5.4 billion over the next six months to support its response to COVID-19 and help tackle waiting lists, the Prime Minister and Health and Social Care Secretary Sajid Javid have announced today.
› Verified 5 days ago
Entity Name | Texas Tech University Health Sciences Center Odessa |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1407845084 PECOS PAC ID: 8426044256 Enrollment ID: O20040607001561 |
News Archive
Researchers from the Polytechnic Institute of New York University and NYU have received a grant from the National Institutes of Health (NIH) to further a novel approach to understanding the genetic underpinnings of diseases including cancer and diabetes.
Neuralstem, Inc. announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin two Phase I safety trials to test NSI-189, its first small molecule compound, for the treatment of major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression.
Canadian students are back in the classroom, but some will find the experience a challenge. It's estimated that as many as six per cent of school age children have poor coordination that affects their ability to learn.
The NHS will receive an extra £5.4 billion over the next six months to support its response to COVID-19 and help tackle waiting lists, the Prime Minister and Health and Social Care Secretary Sajid Javid have announced today.
› Verified 5 days ago
Entity Name | Mch Professional Care Hospital Based |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1447547773 PECOS PAC ID: 1557535127 Enrollment ID: O20111116000437 |
News Archive
Researchers from the Polytechnic Institute of New York University and NYU have received a grant from the National Institutes of Health (NIH) to further a novel approach to understanding the genetic underpinnings of diseases including cancer and diabetes.
Neuralstem, Inc. announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin two Phase I safety trials to test NSI-189, its first small molecule compound, for the treatment of major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression.
Canadian students are back in the classroom, but some will find the experience a challenge. It's estimated that as many as six per cent of school age children have poor coordination that affects their ability to learn.
The NHS will receive an extra £5.4 billion over the next six months to support its response to COVID-19 and help tackle waiting lists, the Prime Minister and Health and Social Care Secretary Sajid Javid have announced today.
› Verified 5 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Ramachandra Rahul Vachan Chemitiganti, MD 701 W 5th St, Odessa, TX 79763-4206 Ph: (432) 335-1777 | Dr Ramachandra Rahul Vachan Chemitiganti, MD 701 W 5th St, Odessa, TX 79763-4206 Ph: (432) 335-1777 |
News Archive
Researchers from the Polytechnic Institute of New York University and NYU have received a grant from the National Institutes of Health (NIH) to further a novel approach to understanding the genetic underpinnings of diseases including cancer and diabetes.
Neuralstem, Inc. announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin two Phase I safety trials to test NSI-189, its first small molecule compound, for the treatment of major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression.
Canadian students are back in the classroom, but some will find the experience a challenge. It's estimated that as many as six per cent of school age children have poor coordination that affects their ability to learn.
The NHS will receive an extra £5.4 billion over the next six months to support its response to COVID-19 and help tackle waiting lists, the Prime Minister and Health and Social Care Secretary Sajid Javid have announced today.
› Verified 5 days ago
Augusto C Sepulveda, M.D. Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 8050 E Highway 191, Suite 200, Odessa, TX 79765 Phone: 432-337-5411 Fax: 432-337-0301 | |
Suresh Prasad, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 403 Pittsburg Ave, Odessa, TX 79761 Phone: 432-332-3400 Fax: 432-332-6500 | |
Dr. Armugam Prasad Mekala, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 500 W 4th St, Odessa, TX 79761 Phone: 432-640-4000 Fax: 432-640-4778 | |
Dr. Timothy Kilian George, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 301 N Washington Ave, Odessa, TX 79761 Phone: 432-335-8275 Fax: 432-334-0687 | |
Dr. James Kenneth Burks, M.D. Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 701 W 5th St, Odessa, TX 79763 Phone: 432-335-1777 Fax: 432-335-1815 | |
Sam Eun Kim, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 8050 E Highway 191, Ste 200, Odessa, TX 79765 Phone: 432-337-5411 Fax: 432-561-5014 | |
Dr. Pankaj Khandelwal, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 301 N Washington Ave, Odessa, TX 79761 Phone: 432-335-8275 Fax: 432-334-0687 |